To the full analysis
Regeneron Pharmaceuticals stock: growth
REGNRegeneron Pharmaceuticals reported $14.34B in revenue for fiscal 2025, up 1% on the prior year, up 11% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
33%
per year from 2006 to 2025, per share 28.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
32.2%
per year from 2006 to 2025, per share 28.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 11.0% | 13.3% | 33.0% |
| Revenue per share | 11.7% | 14.4% | 28.9% |
| Earnings | 5.1% | 21.6% | no data |
| Earnings per share | 5.7% | 21.4% | no data |
| Free cash flow | 15.3% | 20.1% | 32.2% |
| Free cash flow per share | 15.9% | 21.3% | 28.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $63.45M | −$102.34M | $20.26M |
| 2007 | $125.02M | −$105.6M | $8.93M |
| 2008 | $238.46M | −$82.71M | −$123.94M |
| 2009 | $379.27M | −$67.83M | −$169.55M |
| 2010 | $459.07M | −$104.47M | −$3.35M |
| 2011 | $445.82M | −$221.76M | −$198.9M |
| 2012 | $1.38B | $750.27M | −$123.95M |
| 2013 | $2.1B | $424.36M | $432.27M |
| 2014 | $2.82B | $348.07M | $419.43M |
| 2015 | $4.1B | $636.06M | $652.85M |
| 2016 | $4.86B | $895.52M | $974M |
| 2017 | $5.87B | $1.2B | $1.03B |
| 2018 | $6.71B | $2.44B | $1.81B |
| 2019 | $6.56B | $2.12B | $2B |
| 2020 | $8.5B | $3.51B | $2B |
| 2021 | $16.07B | $8.08B | $6.53B |
| 2022 | $12.17B | $4.34B | $4.42B |
| 2023 | $13.12B | $3.95B | $3.67B |
| 2024 | $14.2B | $4.41B | $3.66B |
| 2025 | $14.34B | $4.5B | $4.08B |
Revenue by segment
How Regeneron Pharmaceuticals, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Collaboration Revenue51%
- Product44%
- Product and Service, Other5%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| Collaboration Revenue | $5.5B | $6.06B | $7.33B | 51.1% |
| Product | $7.08B | $7.63B | $6.31B | 44% |
| Product and Service, Other | $536.1M | $515M | $702.6M | 4.9% |
| Total revenue | $13.12B | $14.2B | $14.34B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 5 Jun 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.